BRIEF published on 04/16/2025 at 14:35, 1 year 4 months ago Pathfinder Ventures Welcomes Construction Expert Ben Elzen to Board Board Of Directors Pathfinder Ventures Ben Elzen Construction Expertise Manufactured Housing
BRIEF published on 04/16/2025 at 14:35, 1 year 4 months ago Pathfinder Ventures accueille Ben Elzen, expert en construction, au sein de son conseil d'administration Conseil D'administration Pathfinder Ventures Ben Elzen Expertise En Construction Maisons Préfabriquées
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago Leadership Change at KAP AG Management Board Leadership Change KAP AG Surface Technologies Marten Julius
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago Changement de direction chez KAP AG Conseil D'administration Changement De Direction KAP AG Technologies De Surface Marten Julius
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago GameSquare Partners with GGTech to Expand Esports Events in the U.S. Strategic Partnership U.S. Market Esports Events GAMERGY 2026 University Esports
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago GameSquare s'associe à GGTech pour développer les événements e-sport aux États-Unis Partenariat Stratégique Marché Américain Événements E-sport GAMERGY 2026 Esports Universitaires
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago NOA Lithium Brines Partners with Hatch for Rio Grande Project Assessment Preliminary Economic Assessment Rio Grande Project NOA Lithium Brines Lithium Carbonate Production Hatch Limited
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago NOA Lithium Brines s'associe à Hatch pour l'évaluation du projet Rio Grande Projet Rio Grande Evaluation Économique Préliminaire Saumures De Lithium NOA Hatch Limited Production De Carbonate De Lithium
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
BRIEF published on 04/16/2025 at 14:05, 1 year 4 months ago MIRA Pharmaceuticals publie des données prometteuses sur le kétamir-2 pour la neuropathie diabétique Essais Cliniques MIRA Pharmaceuticals Ketamir-2 Neuropathie Diabétique Traitements Non Opioïdes
Published on 09/11/2026 at 17:00, 2 hours 30 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 2 hours 30 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 4 hours 5 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 4 hours 30 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 5 hours ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 18:15, 1 hour 15 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 1 hour 30 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 18:00, 1 hour 30 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 12 hours 30 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 12 hours 30 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 12 hours 30 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 12 hours 30 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
